HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents.

Abstract
The 1997 European Society of Cardiology guidelines emphasised medical therapy as the mainstay of treatment of stable angina. Until recently, the antianginal drugs available to control symptoms (nitrates, beta-blockers and calcium antagonists) have all been haemodynamic agents that eliminate or reduce angina attacks principally by decreasing myocardial oxygen demand. They may also improve myocardial perfusion. The haemodynamic agents are often used in combination. However, there is conflicting evidence for the efficacy of combination treatment. Two recently published large clinical studies, the Total Ischaemic Burden European Trial (TIBET) study and the International Multicenter Angina Exercise (IMAGE) study, suggest that combined haemodynamic treatment is no more effective than optimal monotherapy. The results from IMAGE suggest that most of the additional effect observed with combined therapy was attributable to recruitment by the second drug of patients who had not responded to monotherapy, and that most patients continued to have a disturbing frequency of anginal attacks after receiving combined therapy. Metabolic agents are a new class of drugs that directly modify the use of energy substrates in the heart, lessening ischaemic injury and improving cardiac performance during ischaemia. Due to their non-haemodynamic mode of action, metabolic agents such as trimetazidine or L-carnitine may provide independent benefit in ischaemia when used as monotherapy or additional benefit when used in combination with a conventional agent. Clinical trials have shown that combined haemodynamic and metabolic treatment is more effective than combined haemodynamic therapy and is well tolerated. It is suggested that combination haemodynamic and metabolic therapy is a logical new approach to patients whose angina is inadequately controlled despite optimal haemodynamic therapy.
AuthorsG Jackson
JournalInternational journal of clinical practice (Int J Clin Pract) Vol. 55 Issue 4 Pg. 256-61 (May 2001) ISSN: 1368-5031 [Print] India
PMID11406911 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Nitrates
  • Vasodilator Agents
  • Trimetazidine
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Angina Pectoris (drug therapy)
  • Calcium Channel Blockers (therapeutic use)
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Humans
  • Nitrates (therapeutic use)
  • Treatment Outcome
  • Trimetazidine (therapeutic use)
  • Vasodilator Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: